Cross-institution positioning
Mar 27, 2026Reduction leaning. 1 accumulating, 1 reducing across 2 comparable institutions.
Source: Schedule 13 researchTonix Pharmaceuticals Holding Corp.
Latest stored close $7.30 as of Oct 9, 2026 View live quote ↗
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
Reduction leaning. 1 accumulating, 1 reducing across 2 comparable institutions.
Source: Schedule 13 research2 increased/new, 0 reduced/exited across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsOver the last 90 days, SEC-coded non-derivative P/S activity includes 2 purchases by 2 reporting owners and 0 sales by 0 reporting owners. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/58 non-amendment material events in the last 90 days; Latest classified evidence: Other event. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataRevenue +577.9% YoY; Net income -43.4% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsRecent close is 11% through its reported 52-week range; -58.1% over one year.
Source: Stored historical price seriesFiled Mar 27, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
See each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Comparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Compare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | LEDERMAN SETH | POpen-market or private purchase | Common Stock, $0.001 par value | 2.0K | $13.79 | Indirect | Aug 31, 2026 |
| Aug 20, 2026 | BAGGER RICHARD H | POpen-market or private purchase | Common Stock, par value $0.001 | 1.0K | $12.60 | Direct | Aug 24, 2026 |
| Jun 30, 2026 | SAENGER BRADLEY | JOther transaction | Common Stock, $0.001 par value | 1.5K | $10.91 | Direct | Jul 9, 2026 |
| Jun 12, 2026 | Taylor Carolyn E. | POpen-market or private purchase | Common Stock, $0.001 par value | 1.4K | $10.55 | Direct | Jun 15, 2026 |
| Jun 9, 2026 | LEDERMAN SETH | POpen-market or private purchase | Common Stock, $0.001 par value | 5.0K | $11.79 | Direct | Jun 9, 2026 |
| Jun 8, 2026 | Stillwell Richard Newcomb | POpen-market or private purchase | Common Stock, $0.001 par value | 5.0K | $11.65 | Direct | Jun 9, 2026 |
| May 12, 2026 | Stillwell Richard Newcomb | AGrant, award, or other acquisition · derivative | Stock Option | 22.7K | $0.00 | Direct | May 14, 2026 |
| May 12, 2026 | OLUKOTUN ADEOYE Y | AGrant, award, or other acquisition · derivative | Stock Option | 22.7K | $0.00 | Direct | May 14, 2026 |
| May 12, 2026 | Bell Margaret Smith | AGrant, award, or other acquisition · derivative | Stock Option | 22.7K | $0.00 | Direct | May 14, 2026 |
| May 12, 2026 | Hunter James Randolph Jr | AGrant, award, or other acquisition · derivative | Stock Option | 22.7K | $0.00 | Direct | May 14, 2026 |
| May 12, 2026 | Treco James | AGrant, award, or other acquisition · derivative | Stock Option | 22.7K | $0.00 | Direct | May 14, 2026 |
| May 12, 2026 | GRANGE DAVID L | AGrant, award, or other acquisition · derivative | Stock Option | 22.7K | $0.00 | Direct | May 14, 2026 |
| May 12, 2026 | BAGGER RICHARD H | AGrant, award, or other acquisition · derivative | Stock Option | 22.7K | $0.00 | Direct | May 14, 2026 |
| May 12, 2026 | Taylor Carolyn E. | AGrant, award, or other acquisition · derivative | Stock Option | 22.7K | $0.00 | Direct | May 14, 2026 |
| Mar 31, 2026 | LEDERMAN SETH | POpen-market or private purchase | Common Stock, $0.001 par value | 5.0K | $12.62 | Indirect | Apr 1, 2026 |
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Oct 2, 2026 | 8-K | 8.01 | Other event | — | Filing |
| Sep 22, 2026 | 8-K | 8.01, 9.01 | Other event; Financial statements / exhibits | — | Filing |
| Sep 8, 2026 | 8-K | 8.01, 9.01 | Other event; Financial statements / exhibits | — | Filing |
| Aug 18, 2026 | 8-K | 5.02, 8.01 | Director or executive change; Other event | — | Filing |
| Aug 10, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Aug 3, 2026 | 8-K | 7.01, 8.01, 9.01 | Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
| Jul 21, 2026 | 8-K | 5.02 | Director or executive change | — | Filing |
| Jul 13, 2026 | 8-K | 7.01, 8.01, 9.01 | Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
| Jul 1, 2026 | S-8 | — | Employee-plan securities registration | Equity | Filing |
| Jun 29, 2026 | 8-K | 7.01, 8.01, 9.01 | Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
| Jun 8, 2026 | 8-K | 7.01, 8.01, 9.01 | Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
| May 27, 2026 | 8-K | 7.01, 8.01, 9.01 | Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
| Period | Revenue | YoY |
|---|---|---|
| Ended Jun 30, 2026 | $13.5M | +577.9% |
| Ended Mar 31, 2026 | $6.9M | +183.2% |
| Ended Sep 30, 2025 | $3.3M | +16.6% |
| Ended Jun 30, 2025 | $2.0M | -9.5% |
| Period | Revenue | YoY |
|---|---|---|
| Ended Dec 31, 2025 | $13.1M | +29.8% |
| Ended Dec 31, 2024 | $10.1M | +29.9% |
| Ended Dec 31, 2023 | $7.8M | — |
Dated price context from the historical market series already collected for this security.
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Vanguard Group CIK0000102909 | Mar 13, 2026 observed Mar 27, 2026 filed · 14d Schedule 13G amendment | Reported reduction | 11 -673.6K | 12.00% +6.98 pts | $13.24 | $12.88 | $7.30 |
| Vanguard Group CIK0000102909 | Dec 31, 2025 observed Jan 30, 2026 filed · 30d Schedule 13G amendment | Reported accumulation | 673.6K +116.6K | 5.02% -1.33 pts | $15.62 | $17.24 | $7.30 |
| BlackRock CIK0002012383 | Dec 31, 2025 observed Jan 21, 2026 filed · 21d Schedule 13G amendment | Reported accumulation | 854.6K +174.5K | 12.00% 0.00 pts | $15.62 | $18.17 | $7.30 |
Compare TNXP with other securities showing similar institutional activity or recent accumulation across several tracked institutions.